About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 1871 record(s)
Req # A-2021-000129
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-118199-773.Organization: Health Canada
November 2022
Req # A-2021-000190
Adverse Drug Reactions (ADRs). Report numbers: E2B_03385629, 000916101, 000923686, E2B_02708380, E2B_03308447, E2B_03328945, E2B_03411903, E2B_03460157, E2B_00798954, 000923623, 000923701.Organization: Health Canada
November 2022
Req # A-2021-000442
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-118199-773.Organization: Health Canada
November 2022
Req # A-2021-000582
Adverse Drug Reactions (ADRs) for Cubicin. Report numbers: 000711663, 000715976, 000716264, E2B_01751860, E2B_0178632, E2B_01786326, E2B_02155091, E2B_02012919.Organization: Health Canada
November 2022
Req # A-2021-000855
Adverse Drug Reactions (ADRs) for ZOPICLONE. Report numbers: E2B_03443827, E2B_03452151, E2B_03481460, E2B_03500313, E2B_03452066, 000919934, E2B_03488470, E2B_03448502, E2B_03459679, E2B_03395985, E2B_03402109.Organization: Health Canada
November 2022
Req # A-2021-000971
Adverse Drug Reactions (ADRs) for Abilify. Report numbers: E2B_03844181, E2B_03844386, E2B_03847698, E2B_03847864, E2B_03851699, E2B_03942512, E2B_03948232, E2B_03851914, E2B_03852086, E2B_03860500, E2B_03903112, E2B_03949189, 000950033. ADRs for…Organization: Health Canada
November 2022
Req # A-2021-001175
Adverse Drug Reactions (ADRs). Report numbers: 000962849, E2B_04284085, E2B_04302866, E2B_04355814, E2B_04342959, 000962490, E2B_04292436, E2B_04230821, 000956864, E2B_04230011, E2B_04245764, E2B_04270850, E2B_04319473, E2B_04325811, E2B_04249368,…Organization: Health Canada
November 2022
Req # A-2021-001972
Adverse Drug Reactions (ADRs). Report numbers: E2B_02678266, E2B_02806936, E2B_02628528, E2B_00013898.Organization: Health Canada
November 2022
Req # A-2021-002001
Adverse Drug Reactions (ADRs) for IRBESARTAN, INFLUENZA VACCINE TRIVALENT. Report numbers: E2B_04136141, 000935967.Organization: Health Canada
November 2022
Req # A-2021-002002
Adverse Drug Reactions (ADRs) for Escitalopram. Report numbers: E2B_03749624, 935127, 939513, 939934, E2B_03794891, 939914, 940767, 939356. ADRs for Citalopram. Report numbers: 936397, 935476, E2B_03759699, E2B_03763412, 939955. ADR for…Organization: Health Canada
November 2022